RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$904M
1-Year Est. Return
12.31%
1 Year Est. Return
+12.31%
AUM
$904M
AUM Growth
+$113M
(+14%)
Holding
103
Top Buys
| 1 | +$14.1M | |
| 2 | +$13.9M | |
| 3 | +$11.1M | |
| 4 |
Axsome Therapeutics
AXSM
|
+$9.96M |
| 5 |
Thermo Fisher Scientific
TMO
|
+$9.17M |
Top Sells
| 1 | +$15.8M | |
| 2 | +$13.9M | |
| 3 | +$11.4M | |
| 4 |
VRNA
Verona Pharma
VRNA
|
+$10.1M |
| 5 |
Gilead Sciences
GILD
|
+$9.77M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Arcellx
ACLX
$3.91B
| $5.36M | 0.59% |
65,250
-2,000
|
|
||
52
Apellis Pharmaceuticals
APLS
$2.75B
| $5.26M | 0.58% |
232,250
+139,000
|
|
||
53
Penumbra
PEN
$14.1B
| $5.19M | 0.57% |
20,500
-1,000
|
|
||
54
Structure Therapeutics
GPCR
$6.38B
| $5.04M | 0.56% |
180,100
+45,000
|
|
||
|
MRUS
55
DELISTED
Merus
MRUS
| $5.04M | 0.56% |
53,500
-62,500
|
|
||
56
Bruker
BRKR
$7.65B
| $5.01M | 0.55% |
154,315
+31,000
|
|
||
57
Natera
NTRA
$33.7B
| $4.99M | 0.55% |
31,000
-26,500
|
|
||
58
Privia Health
PRVA
$2.94B
| $4.84M | 0.54% |
194,189
+103,000
|
|
||
59
Nuvalent
NUVL
$8.27B
| $4.54M | 0.5% |
52,500
|
|
||
60
Inspire Medical Systems
INSP
$2.31B
| $4.53M | 0.5% |
61,000
+30,500
|
|
||
61
Kura Oncology
KURA
$751M
| $4.34M | 0.48% |
490,000
+240,000
|
|
||
62
Mirum Pharmaceuticals
MIRM
$4.87B
| $4.12M | 0.46% |
56,255
-9,500
|
|
||
63
RadNet
RDNT
$5.65B
| $3.81M | 0.42% |
50,000
+4,000
|
|
||
64
Vera Therapeutics
VERA
$3.37B
| $3.78M | 0.42% |
+130,000
|
|
||
65
IQVIA
IQV
$40.1B
| $3.7M | 0.41% |
19,500
+6,500
|
|
||
66
Vericel Corp
VCEL
$1.91B
| $3.68M | 0.41% |
117,000
+59,000
|
|
||
67
Ultragenyx Pharmaceutical
RARE
$2.34B
| $3.59M | 0.4% |
119,400
+26,300
|
|
||
68
BioNTech
BNTX
$29.1B
| $3.54M | 0.39% |
35,870
|
|
||
69
Rhythm Pharmaceuticals
RYTM
$6.87B
| $3.53M | 0.39% |
+35,000
|
|
||
70
TG Therapeutics
TGTX
$4.95B
| $3.36M | 0.37% |
93,000
-22,000
|
|
||
71
United Therapeutics
UTHR
$20.2B
| $3.35M | 0.37% |
+8,000
|
|
||
72
Xenon Pharmaceuticals
XENE
$3.23B
| $3.25M | 0.36% |
81,000
+46,000
|
|
||
73
Nurix Therapeutics
NRIX
$1.88B
| $3.21M | 0.36% |
347,500
+162,500
|
|
||
74
Guardant Health
GH
$14.9B
| $3.12M | 0.35% |
+50,000
|
|
||
75
Alkermes
ALKS
$5.55B
| $2.82M | 0.31% |
94,000
+55,000
|
|